Well-designed, randomized, controlled studies
have demonstrated decreases in the risk of vertebral
fractures of between 35% and 70%, and a hip fracture
risk reduction of 51% has been noted with alendronate.11,12 The IV formulation, zoledronate, has also
been shown to decrease the rate of new vertebral
fractures and hip fractures, by 70% and 41%,
respectively.